The Man Fighting Measles One Breath at a Time

Anonymous — Tue, 01 Mar 2011 17:18:17 +0000

The Man Fighting Measles One Breath at a Time Anonymous (not verified) Tue, 03/01/2011 - 10:18

Jennie Lay

Professor Bob Sievers started out studying moon dust as part of NASA’s Apollo lunar analysis program. Today he’s turning vaccines into tiny dust-like particles to save millions of lives and decimate deadly diseases.

Measles is sitting firmly in Sievers’ vision, with the potential to add vaccinations for human papillomavirus (HPV) and influenza to his arsenal in the foreseeable future. The ��-Boulder chemistry and biochemistry professor and his team have devised a new vaccine formulation that makes it possible for patients to inhale vaccine microparticles instead of being injected.

They’ve also created the PuffHaler™, a cheap, disposable and easily transportable device to administer single-dose vaccines by forming an aerosol to inhale. It’s a technological one-two punch that could knock out needles to vaccinate for measles and other diseases.

Facing a resurgence of measles

The World Health Organization reports vaccination has prevented an estimated 4.3 million measles deaths in less than a decade. Worldwide, measles deaths fell by 78 percent between 2000 and 2008 (from an estimated 733,000 annually to 164,000), and most regions have achieved United Nations goals of reducing measles mortality by 90 percent as of 2010.

But Southeast Asia and increasingly Africa are falling short. India accounts for nearly two-thirds of global measles deaths in children and infants, and 10 percent of India’s preschool-aged deaths are measles-related. WHO Director-General Dr. Margaret Chan notes “signs of stalling momentum” and warns of a resurgence of this highly contagious disease if vaccination efforts are not sustained.

When the Bill and Melinda Gates Foundation announced the Grand Challenges in Global Health six years ago, a significant source of funding emerged to tackle major obstacles in children’s and women’s health care worldwide. Administering needle-free drugs and eliminating the need for refrigeration were two key missions of the challenge that helped fund Sievers’ $20 million inhalable vaccine research effort.

Pending government approvals, the inhalable vaccine is slated for Phase I clinical trials later this year with the Serum Institute in India, the world’s largest producer of vaccines.

Bob Sievers, with help from his 11-year-old grandson Benjamin Louis Sievers, demonstrates how vaccines can be delivered by inhaling from a bag. A ��-Boulder chemistry and biochemistry professor and CEO of Aktiv-Dry, Sievers also is an inventor and sculptor who was elected twice by the people of Colorado to serve as regent.

“He’s done a remarkable job advancing into the clinical phase,” says Michael Gottlieb, associate director of science and deputy director of the Grand Challenges in Global Health initiative for the Foundation for the National Institutes of Health, which has directly managed 20 of these grants, including Sievers’. “It has tremendous implications . . . It’s remarkable to get this far in a relatively short period of time. Many of the grants were more upstream research.”

After clinical trials, Gottlieb says the next hurdle will be influencing government and international aid organization policy decisions and their commitment to get an inhalable vaccine on the ground.

“In a poor country you try to recycle everything, just as we once did here,” Sievers says. “Unfortunately, that includes needles.”

Eliminating needles has the potential to diminish everything from hepatitis and AIDS to cultural, educational and environmental barriers to vaccination.

To abandon needles, Sievers’ team created tiny particles mixed with sugars and amino acids that are both stable and capable of being dispensed through a small puff of air that is inhaled into the lungs from an antistatic plastic bag. Low cost was also imperative: A dose costs no more than 17 cents, which goes toward the vaccine itself, and the delivery device only costs 10 cents. Most of the system is disposable.

“This also is a logistics advance,” Sievers says. “It’s an accident of history that we use rather primitive methods — puncturing flesh — to administer vaccines.”

Time and temperature

The key was being able to create particles that were five microns in diameter or smaller — about the size of a human red blood cell, or about one-tenth the thickness of a fine strand of human hair.

Currently, vaccines are shipped as “cakes,” small pellets that travel around the developing world in ice chests and have to be mixed with purified water. Then they must be used within six hours. That’s six hours for bacteria to grow as the needle goes in and out of the solution amid hot, humid weather.

Sievers’ plan has many advantages. The likelihood of contamination is drastically reduced with single-dose packaging, as is the wastage — vaccines destroyed because of the probability of spoiling. Last year, 400 million doses of measles vaccine were sold in 127 countries. Forty percent of it was wasted because not enough people showed up during a day to use up all the doses mixed in the morning.

“Temperature and time are your enemies. Moisture, too,” Sievers says.

The inhalable vaccine is dried under clean conditions, so there are fewer chances for bacterial growth, and there is a lower risk for infection because there is no piercing of the skin.

Now the findings of Sievers and an international team of about 25 scientists, engineers and physicians whom he led as a principal investigator were published by the Proceedings of the National Academy of Sciences in the Jan. 31, 2011, issue. The team’s paper, co-authored by Sievers, �� lab manager Stephen Cape (MChemEngr’97, PhD’00), scientists from Johns Hopkins University, Centers for Disease Control and Prevention and others, describes the first successful inhalable dry powder vaccine for protection against measles in Rhesus macaques.

“I work in a very applied and interdisciplinary area,” Sievers says. “This paper is a beautiful example of that.”

It's an accident of history that we use primitive methods — puncturing flesh — to administer vaccines."

A measles-free world

Sievers says his scientific interests over the years have been guided by a commitment to pursue socially relevant projects leading to a better environment. Moon dust led to aerosol studies where he looked at atmospheric chemistry and the effects of inhaling pollutants.

When he started noticing the pharmaceutical industry showing up at meetings alongside atmospheric scientists, he crossed into the medical field. With ��’s blessing, Sievers has since founded a private spinoff company called Aktiv-Dry LLC to develop needle-free vaccine delivery systems and new formulations of stable vaccines, antivirals and antibiotics.

All of this was a natural progression for Sievers who served as a �� regent from 1990 to 2002, during which time he helped acquire the closed Fitzsimons Army Base for ��’s new medical school. He also directed the �� Cooperative Institute for Research in Environmental Sciences (CIRES) for 13 years. CIRES researchers focus on innovation and collaboration in studying all aspects of the Earth and how natural and human-made disturbances impact a changing planet. With the Sievers team moving into new research areas, CIRES added a global health program to its scope of studies.

It’s a legacy not lost on co-author Cape who has worked with Sievers since 2002. Cape personally reformulated the vaccine that was tested on the Rhesus macaques, but he hadn’t originally envisioned his career taking a global health trajectory.

“I really enjoy the mission — that focus on meeting the needs of those who aren’t able to help them themselves,” Cape says, noting the advantages of working with someone who is a scientist, a successful entrepreneur and a solid friend. Ever the Renaissance man, Sievers’ art even looms outside Cape’s lab window — a giant red obelisk marble sculpture on the Norlin Quad.

“He’s definitely someone with big picture ideas,” Cape says, emphasizing the gratification of tedious day-to-day tasks overridden by a larger mission. “Even without the profit margin, saving hundreds of thousands of children’s lives is inspiring.”

One great hope is that eventually people might be able to administer this vaccine to babies younger than nine months because many are infected and die before they are vaccinated.

They are not writing on a blank slate. In 1989, during a measles outbreak in Mexico, the government took emergency measures to vaccinate nearly three million children using a wet mist made with an air compressor available at local hardware stores. It was a crisis, and no one kept meticulous records, but there hasn’t been another major measles epidemic in Mexico since then. It’s anecdotal, but it gives Sievers hope.

“This could save lives. We lose, just due to measles, several hundred people a day,” Sievers says. “Our dream is a measles-free world, and that could happen if the vaccine coverage is sufficient.”

That would require vaccinating about 90 percent of a population for “herd immunity” or nearly 100 percent for eradication. But with the ease of the new inhalable measles vaccine system he says he would expect coverage to become a lot better.

“You don’t have to be good enough to give a shot,” Sievers says. “Anybody could give this — just breathe from a bag.”

Jennie Lay (MJour’05) is a freelance journalist based in Steamboat Springs.

Photo by Glenn Asakawa

Professor Bob Sievers has invented an inhalable measles vaccine that could save thousands of lives.

Off

Traditional

White

Why Inject a Vaccine When You Can Inhale it?

Anonymous — Wed, 01 Sep 2010 06:00:00 +0000

Why Inject a Vaccine When You Can Inhale it? Anonymous (not verified) Wed, 09/01/2010 - 00:00

Staff

�� Boulder researchers believe an inhalable measles vaccine slated for human clinical trials in Pune, India, will lead to similar vaccines for other illnesses.

A revolutionary inhalable vaccine developed at �� for measles prevention could lead to other inexpensive, easy-to-administer vaccines and save thousands of lives throughout the world.

Human clinical trials for the vaccine began this summer in India, thanks to the efforts of ��-Boulder chemistry and biochemistry professor Robert Sievers, who has spent years developing the inhalable measles vaccine.

Why India? The country accounts for two-thirds of global deaths from measles in children and infants, which totaled 164,000 in 2008, according to the World Health Organization.

“One of our primary goals of this project is to get rid of needles and syringes because they frighten some people, they hurt, they can transmit diseases and there are issues with needle disposal,” Sievers says.

The cost of the inhalant dose for measles is about 26 cents, roughly the same price as an injectable dose. To make it, Sievers’ team mixed “supercritical” carbon dioxide with a weakened form of the measles virus. The process produces microscopic bubbles and droplets that are dried to make the inhalable powder. It is dispensed into patients’ mouths using a small, cylindrical plastic sack with an opening like the neck of a plastic water bottle.

A spinoff of Sievers’ research is Aktiv-Dry, which he founded in 2002 with �� pharmacy professor John Carpenter and Brian Quinn, the company president. Sievers notes 40 students have earned doctorates under him, and “it was those students and their work that really positioned us at the right time to gain significant funding for this project.”

A revolutionary inhalable vaccine developed at �� for measles prevention could lead to other inexpensive, easy-to-administer vaccines and save thousands of lives throughout the world.

Off

Traditional

White